You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

CLINICAL TRIALS PROFILE FOR LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00117273 ↗ A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens Completed Duramed Research Phase 3 2005-06-01 This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).
NCT00128934 ↗ Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-08-01 The purpose of this study is to determine whether levonorgestrel (LNG)/ethinyl estradiol (EE) is effective in treating the symptoms of severe premenstrual syndrome (PMS).
NCT00161681 ↗ Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-07-01 The purpose of this study is to determine whether LNG/EE is effective in the treatment of menstrual cycle related symptoms.
NCT00195559 ↗ Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-09-01 The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE) is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol

Condition Name

Condition Name for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol
Intervention Trials
Contraception 15
Healthy 11
Drug Interactions 3
Endometriosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol
Intervention Trials
HIV Infections 3
Endometriosis 3
Premenstrual Syndrome 3
Menstruation Disturbances 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol

Trials by Country

Trials by Country for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol
Location Trials
United States 129
China 12
Germany 12
Mexico 6
Canada 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol
Location Trials
Florida 12
California 8
Arizona 7
Texas 7
Ohio 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol

Clinical Trial Phase

Clinical Trial Phase for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol
Clinical Trial Phase Trials
Phase 4 7
Phase 3 16
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol
Clinical Trial Phase Trials
Completed 42
Recruiting 7
Withdrawn 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol

Sponsor Name

Sponsor Name for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 8
Bayer 5
Agile Therapeutics 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol
Sponsor Trials
Industry 55
Other 20
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Levonorgestrel and Ethinyl Estradiol: Clinical Trials, Market Analysis, and Projections

Introduction

Levonorgestrel and ethinyl estradiol are two hormones commonly used in combination hormonal contraceptives. These medications are available in various forms, including oral tablets, transdermal patches, and other delivery systems. This article will delve into the clinical trials, market analysis, and projections for these drugs.

Clinical Trials Overview

Pharmacokinetics and Drug Interactions

A recent clinical trial (NCT06657105) conducted by AstraZeneca investigates the pharmacokinetics of ethinyl estradiol and levonorgestrel when co-administered with baxdrostat. This open-label, fixed-sequence study involves healthy female participants and assesses the effect of multiple doses of baxdrostat on the pharmacokinetics of a single dose of combined oral ethinyl estradiol and levonorgestrel[1].

Efficacy and Safety of Transdermal Delivery

A phase 3 clinical trial (NCT02158572) evaluated the efficacy, safety, and tolerability of a transdermal delivery system (TDS) containing levonorgestrel and ethinyl estradiol. The study enrolled 2032 women and found that the TDS was effective in preventing pregnancy, although efficacy was reduced in women with a BMI ≥30 kg/m². The study also reported hormone-related adverse events such as nausea and headache, and a small number of thromboembolic events in women with higher BMIs[4].

Extended-Cycle Oral Contraceptives

The extended-cycle oral contraceptive Seasonale, which contains 30 mcg of ethinyl estradiol and 150 mcg of levonorgestrel, has been studied extensively. A one-year study showed that the pregnancy rates for the extended cycle regimen were similar to those of conventional regimens, with a rate of 0.9% compared to 1.3% for conventional regimens[2].

Market Analysis

Market Presence and Forms

Levonorgestrel and ethinyl estradiol are widely available in various forms, including oral tablets, patches, and other delivery systems. The oral tablets are often dispensed in 21-day, 28-day, or extended-cycle regimens. For example, Seasonale is an extended-cycle regimen where women take active hormone tablets for 84 consecutive days followed by 7 hormone-free days, resulting in one menstrual period every three months[2].

Generic and Branded Options

The market includes both generic and branded options. Generic versions, such as those marketed under the Nortrel trademark, offer similar formulations at potentially lower costs. For instance, Nortrel 1/35 and Nortrel 0.5/35 are available in 21-day and 28-day regimens, respectively[3].

Pricing and Accessibility

The pricing of these contraceptives can vary, with branded options like Seasonale being comparable to conventional brand oral contraceptives but more expensive than generic alternatives. The extended-cycle regimen of Seasonale, however, offers the convenience of fewer refills per year, which can be an advantage for some users[2].

Projections and Future Trends

Increasing Demand for Convenience

There is a growing demand for convenient and user-friendly contraceptive options. Extended-cycle regimens like Seasonale and transdermal patches are expected to gain popularity due to their ease of use and reduced frequency of menstrual cycles[2][3].

Advances in Delivery Systems

Advancements in delivery systems, such as the transdermal patch TWIRLA, are likely to continue. These systems offer alternative methods for women who may have difficulty adhering to daily oral regimens or prefer a different delivery method. The approval of TWIRLA by the FDA highlights the ongoing innovation in this field[4].

Regulatory Environment

Regulatory approvals play a crucial role in the market dynamics of these drugs. The FDA's approval process ensures that new formulations and delivery systems meet safety and efficacy standards. For example, the approval of TWIRLA for women with BMI <30 kg/m² underscores the importance of regulatory oversight in expanding contraceptive options[4].

Safety and Tolerability

Common Adverse Events

Clinical trials have identified common adverse events associated with levonorgestrel and ethinyl estradiol, including nausea, headache, and unexpected bleeding. These events are generally consistent with other combined hormonal contraceptives. However, women with higher BMIs may experience reduced efficacy and an increased risk of certain adverse events, such as thromboembolic events[2][4].

Body Mass Index (BMI) Considerations

The efficacy and safety profile of these contraceptives can be influenced by the user's BMI. Studies have shown that women with a BMI ≥30 kg/m² may experience reduced contraceptive efficacy and an increased risk of certain adverse events. This highlights the importance of considering BMI when prescribing these medications[4].

User Experience and Compliance

Simplified Regimens

Extended-cycle regimens like Seasonale offer a simplified approach to contraception, reducing the number of menstrual cycles and the frequency of refills. This can enhance user compliance and satisfaction, although some women may experience more unexpected bleeding in the initial months of use[2].

Alternative Delivery Systems

Alternative delivery systems, such as transdermal patches, can also improve compliance by providing a method that does not require daily administration. These systems can be particularly beneficial for women who find it challenging to adhere to a daily oral regimen[4].

Key Takeaways

  • Clinical Trials: Ongoing trials focus on pharmacokinetics, efficacy, and safety, particularly with new delivery systems like transdermal patches.
  • Market Analysis: The market includes a range of branded and generic options, with extended-cycle regimens and alternative delivery systems gaining popularity.
  • Projections: Future trends include increased demand for convenient and user-friendly options, advancements in delivery systems, and continued regulatory oversight.
  • Safety and Tolerability: Common adverse events include nausea and headache, with reduced efficacy and increased risk of adverse events in women with higher BMIs.
  • User Experience: Simplified regimens and alternative delivery systems can enhance compliance and user satisfaction.

FAQs

Q: What are the common forms of levonorgestrel and ethinyl estradiol contraceptives?

A: These contraceptives are available in oral tablets, transdermal patches, and other delivery systems.

Q: How does the extended-cycle regimen of Seasonale work?

A: Seasonale involves taking active hormone tablets for 84 consecutive days followed by 7 hormone-free days, resulting in one menstrual period every three months.

Q: Are there any BMI considerations for using levonorgestrel and ethinyl estradiol contraceptives?

A: Yes, women with a BMI ≥30 kg/m² may experience reduced efficacy and an increased risk of certain adverse events.

Q: What are the common adverse events associated with these contraceptives?

A: Common adverse events include nausea, headache, and unexpected bleeding.

Q: How do transdermal patches like TWIRLA compare to oral contraceptives?

A: Transdermal patches offer an alternative method that does not require daily administration, which can improve compliance, but may have reduced efficacy in women with higher BMIs.

Sources

  1. AstraZeneca Clinical Trials: "An Open-label, Fixed Sequence Study to Assess the Effect of Multiple Doses of Baxdrostat on the Pharmacokinetics of Single Doses of Combined Oral Ethinyl Estradiol and Levonorgestrel in Healthy Female Participants of Non-childbearing Potential."
  2. American Academy of Family Physicians: "Ethinyl Estradiol/Levonorgestrel (Seasonale) for Oral Contraception."
  3. Relias Media: "New generic OCs now on the pharmacy shelves."
  4. PubMed: "Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system."

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.